Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 119Squamous Cell Carcinoma of Head and Neck 60Melanoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 46Lung Neoplasms 45Triple Negative Breast Neoplasms 44Neoplasm Metastasis 42Breast Neoplasms 40Neoplasms 36Colorectal Neoplasms 31Head and Neck Neoplasms 27Endometrial Neoplasms 26Carcinoma, Renal Cell 26Ovarian Neoplasms 23Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 20Stomach Neoplasms 15Carcinoma 14Pancreatic Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Brain Neoplasms 11Carcinoma, Squamous Cell 10Cholangiocarcinoma 9Carcinoma, Hepatocellular 9Skin Neoplasms 8Esophageal Squamous Cell Carcinoma 8

Interventions

Injections 8pembrolizumab 4Pemetrexed 4Carboplatin 4Oxaliplatin 3Leucovorin 3Fluorouracil 3trifluridine tipiracil drug combination 2sotorasib 2fludarabine 2Paclitaxel 2Drug Therapy 2Docetaxel 2Bevacizumab 2zimberelimab 1trametinib 1toripalimab 1tislelizumab 1sacituzumab govitecan 1netrin-1 inhibitor NP137 1cemiplimab 1WW Domain-Containing Oxidoreductase 1SYS6006 COVID-19 vaccine 1Panitumumab 1Irinotecan 1Immune Checkpoint Inhibitors 1Etoposide 1Cyclophosphamide 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Solid Tumors × pembrolizumab × 90 days × Clear all
NCT06480552 2026-06-04

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Recruiting
240 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05067283 2026-05-26

KANDLELIT-001

Merck Sharp & Dohme LLC

Phase 1 Recruiting
830 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06795412 2026-05-04

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Pyxis Oncology, Inc

Phase 1/2 Recruiting
220 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡